|
Originally published In Press as doi:10.1074/jbc.M200797200 on May 31, 2002
J. Biol. Chem., Vol. 277, Issue 32, 29132-29138, August 9, 2002
Retroviral Delivery of Connexin Genes to Human Breast Tumor Cells
Inhibits in Vivo Tumor Growth by a Mechanism That Is
Independent of Significant Gap Junctional Intercellular
Communication*
Hong
Qin ,
Qing
Shao ,
Heather
Curtis ,
Jacques
Galipeau§,
Daniel J.
Belliveau ,
Taiqi
Wang§,
Moulay A.
Alaoui-Jamali§, and
Dale W.
Laird ¶
From the Department of Anatomy and Cell Biology,
University of Western Ontario, London, Ontario N6A 5C1, Canada and the
§ Departments of Medicine, Pharmacology, and Therapeutics
and the McGill Centre for Translational Research in Cancer, Lady
Davis Institute for Medical Research, McGill University, Montreal,
Quebec H3T 1E2, Canada
Received for publication, January 24, 2002, and in revised form, May 8, 2002
 |
ABSTRACT |
The mechanism by which gap junction proteins,
connexins, act as potent tumor suppressors remains poorly
understood. In this study human breast tumor cells were found to
exhibit diverse gap junction phenotypes including (a) undetectable Cx43
and no intercellular communication (HBL100); (b) low levels of Cx43 and
sparse intercellular communication (MDA-MB-231); and (c) significant
levels of Cx43 and moderate intercellular communication (Hs578T).
Although retroviral delivery of Cx43 and Cx26 cDNAs to MDA-MB-231
cells did not achieve an expected substantial rescue of intercellular
communication, overexpression of connexin genes did result in a
dramatic suppression of tumor growth when connexin-expressing
MDA-MB-231 cells were implanted into the mammary fat pad of nude mice.
Subsequent immunolocalization studies on xenograph sections revealed
only cytoplasmic stores of Cx43 and no detectable gap junctions.
Moreover, DNA array and Western blot analysis demonstrated that
overexpression of Cx43 or Cx26 in MDA-MB-231 cells
down-regulated fibroblast growth factor receptor-3. Surprisingly, these
results suggest that Cx43 and Cx26 induce their tumor-suppressing
properties by a mechanism that is independent of significant gap
junctional intercellular communication and possibly through the
down-regulation of key genes involved in tumor growth. Moreover, our
studies show that retroviruses are effective vehicles for delivering
connexins to human breast tumor cells, facilitating potential gene
therapy applications.
 |
INTRODUCTION |
Gap junctional intercellular communication
(GJIC)1 plays a crucial role
in direct cell-cell signaling via the exchange of small molecules such
as calcium ions, IP3, and cAMP between the linked cells (1,
2). A family of homologous proteins called connexins comprise the basic
building blocks of gap junctions (1, 2). Connexins are
co-translationally inserted into endoplasmic reticulum membrane and
oligomerized into hemichannels (connexons), which are transported to
the plasma membrane (3). Connexons from two contacting cells dock at
the plasma membrane to form intercellular gap junction channels, which
cluster to form gap junction plaques (3).
Presently, in excess of fifteen connexin genes have been identified and
cloned (1, 2). However, only three connexins, connexin26 (Cx26),
connexin43 (Cx43), and connexin32 (Cx32), have been found in rodent
mammary epithelium in different temporal and spatial patterns (4-8).
Cx43 is localized mainly to myoepithelial cells throughout all of the
stages of mammary gland development, whereas Cx26 is localized
primarily to the luminal cells (6). Expression of Cx26 increases in
pregnancy and peaks during lactation. Cx32 is a minor connexin
expressed in luminal cells, and it can be detected only in lactating
gland (6, 8). Monaghan et al. (5) reported Cx26 and Cx43 to
be the only connexins expressed in the resting human mammary gland.
Connexin expression, gap junction assembly, and GJIC are down-regulated
in a variety of neoplastic cells or primary tumors both in
vivo and in vitro (9-14). In many cases the
restoration of connexin expression and GJIC has reduced tumor growth
and promoted cell differentiation (12). Therefore, connexin genes have
been deemed tumor suppressors. Further evidence supporting the
role of connexins as tumor suppressors came from Cx32 knockout mice, which were found to be more susceptible to liver tumor formation in
comparison to wild-type littermates (15). In the human breast, Wilgenbus et al. (16) reported the lack of Cx43 expression
in malignant tumors. Lee et al. (17) also found that Cx43
mRNA was not detected in several mammary tumor cell lines, and
subtractive hybridization was used to identify Cx26 as a potential
tumor-suppressing molecule (18). Consistent with these studies, we
found a deficiency of Cx43 gap junctions in several human breast
carcinomas (7). Interestingly, Jamieson et al. (19) compared
the expression of Cx43 and Cx26 in normal human breast tissues and
human breast tumor tissues in situ and found that many
invasive carcinomas expressed one of these two connexins but that most
often these connexins were not assembled into gap junctions. These
latter results suggest that a population of transformed mammary
epithelial cells continue to express connexins but have lost the
ability to assemble connexins into functional gap junctions.
If connexin transgene approaches ever are to be used as part of a
potential human breast cancer therapy regimen, it is necessary to
develop a delivery system for introducing connexins in vivo and to determine whether human breast tumor cells are generally capable
of expressing exogenous connexins and forming functional gap junctions.
Although a clear relationship between connexin expression, GJIC, and
carcinogenesis has been elucidated, the understanding of gap junctions
in the development of human breast cancer has yet to be established.
Moreover, it remains unclear whether the tumor-suppressing properties
of connexins is restricted to the ability of connexins to form gap
junction channels.
In the present study we identified human breast cancer cells that
mechanistically exhibit two types of GJIC defects. First, in cells that
lack connexin expression (i.e. HBL100 cells) GJIC could be
restored effectively using a retroviral system to deliver connexins.
However, in cells that were defective in connexin trafficking and gap
junction assembly (i.e. MDA-MB-231) exogenous connexins were
delivered preferentially to lysosomes. Nevertheless, in vivo data revealed that, even in the absence of significant GJIC,
overexpression of connexin genes in MDA-MB-231 human breast tumor cells
suppressed tumor growth as the possible result of down-regulation of
regulatory genes involved in tumor growth.
 |
MATERIALS AND METHODS |
Cell Culture--
All of the cells were grown at 37 °C with
5% CO2 in the recommended medium including RPMI 1640 (Invitrogen) for MDA-MB-231/Hs578T cells and Dulbecco's
modified Eagle's medium (Invitrogen) for normal rat kidney
(NRK), HeLa, and HBL100 cells. The medium was supplemented with 10%
fetal bovine serum (or 10% calf serum for HBL100 cells), 2 mM glutamine, and 100 units/ml penicillin, 100 µg/ml
streptomycin. Human mammalian epithelial cells (HMEC) was purchased
from Clonetic Human Cell Systems (BioWhittaker, Walkersville, MD) and
cultured in the mammary epithelial cell growth medium (BioWhittaker) according to the manufacturer's instructions.
Immunocytochemistry and Confocal Imaging--
Cells were
immunolabeled as described previously by Laird et al. (20)
with anti-Cx43 polyclonal antibodies directed against amino acid
residues 360-382 of Cx43 (21) or antibodies to Cx26 (Zymed
Laboratories Inc., San Francisco, CA). The images were captured
using a Zeiss LSM 410 inverted confocal microscope equipped with a ×63
oil lens as described previously (20).
Single Cell Microinjection--
Single cells were pressure
microinjected with 5% Lucifer Yellow (Molecular Probes, Leiden,
Netherlands) using an Eppendorf microinjection system and a Zeiss
inverted epifluorescent microscope. Digital images were acquired using
a CCD Sensicam. The percentage of microinjected cells that exhibited
dye coupling and the order of dye transfer (first order, cells
contacting the microinjected cell only; second order, cells distant
from the microinjected cells by one cell, etc.) were determined.
Because many of these tumor cells are prone to overlapping and piling
up, dye that spread only to a single neighboring cell was quantified
separately to allow for artifacts that might occur from the inadvertent
penetration of two cells during the microinjection procedure.
cDNA Constructs, Transfection, and Infection--
Cx43 and
Cx26 cDNAs were provided by Dr. C. C. G. Naus. To engineer the
retroviral vectors that encoded Cx43 or Cx26, we removed the enhanced
green fluorescent protein reporter gene from an AP2 viral vector
(22) by NotI digestion. Cx26 cDNA was engineered into
the AP2 vector between BglII restriction sites while Cx43 cDNA was inserted between NotI and CalI.
Recombinant retroviral vectors were transfected into 293GPG package
cell lines to produce virus-containing supernatant that was further
used for infecting the tumor cells as described previously (23). More
than 90% of the mammary tumor cells expressed connexins after three
rounds of viral infection.
Cell Growth and Tumor Formation in Nude Mice--
To examine
cell growth in vitro, 5 × 104 cells were
plated in 35-mm tissue culture dishes and allowed to grow. At days 2, 3, 4, 5, and 6 cells from replicated plates were collected and counted using a Coulter® ZTM 1 particle counter (Beckman-Coulter,
Miami, FL). These data were plotted as the average cell number ± S.E.
For in vivo tumor growth 6-8-week-old female Nu-Nu mice
(18-22 g) were obtained from Charles River Laboratories (St. Zotique, Quebec). The experimental protocol was approved by the Animal Care
Committee of McGill University, Montreal, Quebec. Animals (5-15 per
treatment) were housed 5 to a cage and fed rodent chow and water
ad libitum. After 1 week of acclimatization, a suspension of
1 × 106 MDA-MB-231 viral control tumor cells or
MDA-MB-231 tumor cells expressing Cx43 or Cx26 were transplanted into
the mammary fat pad in a total volume of 0.1 ml of medium. Tumor length
and width were measured every 3-8 days using a caliper accurate to 0.5 mm. Tumor volume was calculated using the formula V = L × W × 0.5W. The experiment was terminated when the control tumors
reached the maximal size allowed. In this mouse study, MDA-MB-231 cells infected with the control retrovirus that did not encode a connexin, one mouse died prematurely and was eliminated from the data set. This
data set was plotted as the average tumor size ± S.E. In the case
of the mice transplanted with MDA-MB-231 expressing either Cx43 or
Cx26, four mice failed to develop a tumor, three mice developed tumors
that were too small to accurately measure, and three mice developed
small tumors.
Immunohistochemistry on Xenograph Sections--
The xenografts
in nude mice were excised, fixed in 4% formalin, embedded in paraffin,
and cut into 4-µm thick sections for immunohistochemistry. Tissue
sections were deparaffinized in xylene, graded alcohol, and water,
boiled in citric acid buffer for antigen retrieval, and blocked by 10%
horse serum. The tissue sections were stained with anti-Cx43 polyclonal
antibodies (Sigma) followed by incubation with biotinylated secondary
anti-rabbit IgG (Vector Laboratories, Burlington, ON). Positive
immunolocalization of Cx43 was determined using the Elite ABC kit
(Vector Laboratories). For contrast, tissue sections were
counterstained with hematoxylin. Finally, all images were acquired
using the Zeiss Axioscope light microscope.
DNA Array and Western Blotting--
Total RNA was extracted from
cells using Trizol Reagent (Invitrogen) for the preparation of
biotin-labeled cDNA probes. Nonrad-GEArray kits were purchased from
SuperArray, Inc. (Bethesda, MD) and supplemented with
positively charged nylon membrane on which cDNA fragments from
genes had been immobilized in duplicate. The membrane used in our study
contained 23 genes closely related to tumor growth and metastasis plus
two positive control genes (GAPDH and -actin) and one negative
control (pUC18). Probe synthesis, hybridization, and chemiluminescent
detection were performed according to the manufacturer's protocol. In
brief, 10 µg of total RNA was reverse-transcribed into biotin-labeled
cDNA probes at 42 °C for 120 min. The hybridization was
performed with denatured cDNA probe at 68 °C overnight after a
1-h incubation of the membrane with sheared salmon sperm at 68 °C.
For detection, the membrane was incubated with AP-streptavidin and then
subjected to CDP-Star chemiluminescence substrate. The results were
analyzed using the Multi-Analyst 1.0.1 software from Bio-Rad. Because
no signal amplification was performed, the membranes were quantified
first by subtracting the average background intensity for the
pUC18-negative control and secondly by examining the signal ratio in
comparison to the internal GAPDH-positive control (see Fig. 2,
bottom right corner of blots). Differential
hybridization levels of over 2-fold were considered physiologically
relevant. Only fibroblast growth factor receptor-3 (FGFR3) and CXCR4
were significantly regulated by both Cx43- and Cx26-expressing cells and pursued further.
For Western blots, cells were lysed in solubilization buffer as
described previously (20, 24, 25), and protein quantification was
determined using BCA protein assay reagent (Pierce). Equal amounts of
proteins were separated by 10% SDS-PAGE and transferred to
nitrocellulose membranes that were subsequently immunoblotted with the
indicated antibodies (anti-Cx43 and anti-FGFR3, Sigma). Specific
antibody binding was determined using the West-Pico chemiluminescence detection system (Pierce). To assure equal gel loading, nitrocellulose membranes were stripped in 62.5 mM Tris-HCl, 2% SDS, and
100 mM -mercaptoethanol, and blots were reprobed for the
housekeeping enzyme GAPDH (Cedarlane Laboratories, Hornby, ON, Canada).
 |
RESULTS |
Characterization of Connexin Expression in Human Breast Tumor
Cells--
We initially characterized the expression of the only known
human breast connexins, Cx26 and Cx43, in three different human breast
tumor cells by immunofluorescent staining and Western blotting. Endogenous Cx43-positive NRK cells were used together with HMEC to
demonstrate the distribution and assembly of Cx43 into gap junction
plaques (Fig. 1, A and
B, arrows). In a subpopulation of Hs578T cells,
Cx43 was capable of assembling into gap junction plaque-like structures
on the cell surface (Fig. 1C, arrows), whereas in
MDA-MB-231 cells intracellular Cx43 was visible, but no gap junction
plaques were observed (Fig. 1D). Immunofluorescence failed
to detect Cx43 in HBL100 cells (Fig. 1E). By immunoblotting, Cx43 was detected in cell lysates from NRK, HMEC, Hs578T, and MDA-MB-231 cells but not in HBL100 cells (Fig. 1F).
Phosphorylated species of Cx43 (slower migrating forms) were apparent
in NRK cells, suggesting significant levels of assembled gap junctions, but the same Cx43 species typically were less abundant or undetectable in tumor cells. The expression of Cx26 protein was not detected in
these three tumor cell lines by immunofluorescence (data not show).

View larger version (121K):
[in this window]
[in a new window]
|
Fig. 1.
Characterization of diverse gap junction
phenotypes in human breast tumor cell lines. Cx43 gap junction
plaques (arrows) were observed between contacting NRK
(A), HMEC (B), and tumor Hs578T (C)
cells. However, MDA-MB-231 carcinomas expressed low levels of
intracellular Cx43 (D), whereas HBL100 cells were devoid of
Cx43 (E). Western blot analyses of cell lysates from NRK,
HMEC, Hs578T, and MDA-MB-231 cells were positive for Cx43, but Cx43 was
not detected in HBL100 cells (F). Bar, 10 µm
|
|
Defective GJIC in Human Breast Tumor Cells--
To examine GJIC in
human breast tumor cells we microinjected live cells with 5% Lucifer
Yellow and examined intercellular dye coupling (Table
I). Cx43- and Cx26-deficient HBL100 cells exhibited only trace amounts of dye coupling to the first order cells (Table I). Moreover, although MDA-MB-231 cells expressed Cx43 this connexin was not assembled into gap junctions as only 6% of
the microinjected cells exhibited dye transfer, and this was further
restricted to first order cells (Table I). Interestingly, even though a
significant number of Hs578T cells expressed Cx43 that was assembled
into gap junction plaques these cells were only 47% coupled, and dye
spreading was restricted to first order cells (Table I). These results
suggest that this tumor cell line is quite heterogeneous with respect
to GJIC. NRK cells were found to be extensively dye coupled (Table I).
Together these findings suggest that each of these tumor cell lines is
significantly or extensively defective in GJIC.
View this table:
[in this window]
[in a new window]
|
Table I
Defective GJIC and differential rescue of GJIC in human breast tumor
cells
Single cells in 90% confluent cultures were microinjected with 5%
Lucifer Yellow. The percentage of microinjected cells demonstrating dye
transfer and the extent of dye transfer was assessed.
|
|
Retroviral Delivery of Connexin Genes Differentially Rescues GJIC
in Human Breast Tumor Cells in Vitro--
In an attempt to rescue the
defects in GJIC we used AP2 retroviruses encoding Cx26 or Cx43 to
deliver these genes into HBL100 and MDA-MB-231 cells. The retroviral
system enabled an efficient targeting of exogenous connexins to both
tumor cell lines with >90% of cell populations expressing the
transgene after three rounds of infection. In HBL100 cells, exogenous
Cx43 (Fig. 2B) or Cx26 (Fig.
2D) were assembled into gap junction plaques
(arrows). Immunoblots revealed that Cx43 was detected in the
cells infected by the Cx43 gene-containing AP2 virus but not in the
control cells (Fig. 2F). Compared with their wild-type cell
counterparts, introduction of either Cx43 or Cx26 genes efficiently
rescued GJIC in HBL100 cells, resulting in over 80% of the
microinjected cells exhibiting dye transfer to second or third order
cells (Table I). In contrast, when Cx43 or Cx26 were expressed in
MDA-MB-231 cells, these cells remained poorly coupled with dye
spreading to only 8-15% of first order cells (Table I). In many
cases, Lucifer Yellow spread to only one neighboring cell when
MDA-MB-231 overexpressed Cx43 or Cx26 (Fig.
3, D and E). The
majority of overexpressed Cx43 in MDA-MB-231 cells remained as a single
band likely representing the unphosphorylated species of Cx43 (Fig.
2E), although slower migrating phosphorylated species of
Cx43 also were evident. Immunolabeling studies revealed that the
exogenous Cx43 (Fig. 2A) or Cx26 (Fig. 2C) were
localized aberrantly to perinuclear intracellular compartments. Double
immunolabeling revealed that Cx26 (Fig. 3, A and
C) colocalized with the lysosomal-associated membrane
protein LAMP-1 (Fig. 3, B and C), demonstrating
that Cx26 had been delivered to lysosomes. Likewise, we showed
previously that Cx43 was delivered to lysosomes in MDA-MB-231 cells
(26). Consequently, the defect in MDA-MB-231 cells is not in connexin
synthesis but rather in their inability to assemble functional gap
junctions efficiently in vitro.

View larger version (112K):
[in this window]
[in a new window]
|
Fig. 2.
Retroviral delivery of Cx43 or Cx26 genes
differentially rescued gap junction assembly in MDA-MB-231 and HBL100
cells. Confocal images revealed that exogenous Cx43 (A)
or Cx26 (C) was transported inefficiently to the cell
surface and assembled into gap junctions in MDA-MB-231 cells while Cx43
(B) and Cx26 (D) were assembled more efficiently
into gap junctions in HBL100 cells (arrows). High levels of
Cx43 were detected after MDA-MB-231 cells were engineered to express
exogenous Cx43; however, most endogenous and exogenous Cx43 remained
unphosphorylated (E). Cx43 was undetected in wild-type
HBL100 cells and in cells infected with the retroviral vector only.
Both phosphorylated and unphosphorylated species of Cx43 were seen in
HBL100 cells infected with the retroviral vector encoding Cx43. Western
blots were immunolabeled for GAPDH to ensure equal loading.
Bar, 10 µm.
|
|

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 3.
Cx26 is delivered to lysosomes and fails to
efficiently rescue GJIC. MDA-MB-231 cells expressing Cx26 were
double-immunolabeled for Cx26 (A) or a resident protein of
lysosomes, LAMP-1 (B). The overlay (C) revealed
that Cx26 is localized primarily to lysosomes. A single
MDA-MB-231 cell expressing Cx26 was pressure-microinjected with 5%
Lucifer Yellow, and dye was observed to spread to one contacting
cell only (D and E, asterisk).
Bar, 10 µm
|
|
Connexin Expression in MDA-MB-231 Cells Dramatically Inhibits Tumor
Cell Growth in Vivo Independently of the Formation of Appreciable Gap
Junctions--
In the absence of functional gap junctions, we examined
the role of connexins in tumor growth control in vitro by
comparing the growth kinetics of connexin-overexpressing cells and
their control counterparts, including wild-type cells or cells infected with the retroviral vector that did not encode a connexin. When MDA-MB-231 cells were engineered to overexpress Cx43 or Cx26 in vitro these cells exhibited growth characteristics similar to the
control (Fig. 4A). However, a
dramatic inhibition of tumor growth was observed when Cx43- or
Cx26-overexpressing MDA-MB-231 cells were implanted into mammary fat
pad of the nude mice (Fig. 4B). In addition to the smaller
tumor volume, in comparison to controls, it took more time for
connexin-expressing cells to develop tumors, and in over 50% of the
mice tested no measurable tumor developed. Xenograph removal and
immunostaining for Cx43 revealed that Cx43-expressing MDA-MB-231 cells
retained the connexin within the cell and did not assemble gap junction
plaques at cell-cell interfaces (Fig. 5,
C and D), whereas only low levels of detectable Cx43 immunostaining were observed on sections of control MDA-MB-231 xenoplant tumors (Fig. 5B). As a positive control, punctate
Cx43-positive gap junctions were readily observed between cardiac
myocytes (Fig. 5A, arrows). Together these
results suggest that connexins exert tumor suppression properties in
MDA-MB-231 cells by a mechanism that is independent of appreciable
GJIC.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 4.
Overexpression of Cx43 or Cx26 did not
significantly inhibit MDA-MB-231 cell growth in vitro
but dramatically suppressed tumor development and growth in
vivo. For in vitro experiments, equal
numbers of wild-type tumor cells and the cells infected with the
retroviral vector lacking connexins or a containing cDNA-encoding
Cx43 or Cx26 were plated in 35-mm culture dishes. At the indicated time
point, cells were collected and counted. No significant suppression of
cell growth was observed in MDA-MB-231 cells that expressed exogenous
connexins (left panel). However, expression of Cx26 or Cx43
inhibited tumor development and growth in vivo when
connexin-expressing MDA-MB-231 cells were implanted into the mammary
fat pad of nude mice (right panel).
|
|

View larger version (150K):
[in this window]
[in a new window]
|
Fig. 5.
Overexpressed Cx43 did not form gap junctions
in vivo. Punctate gap junctions at cell-cell
interfaces (arrows) were observed readily in control
mouse cardiac tissue immunolabeled for Cx43 (A). However,
only low levels of intracellular Cx43 were detected in sections of
control MDA-MB-231 xenoplants (B). Likewise, low
(C) and high (D) magnification images revealed
only intracellular Cx43 in sections of MDA-MB-231 tumors overexpressing
Cx43. No detectable punctate Cx43 gap junction plaques were observed in
these tumors. Bar, 10 µm
|
|
Fibroblast Growth Factor Receptor Was Down-regulated in MDA-MB-231
Cells Overexpressing Cx43 or Cx26--
To examine the molecular
mechanism of a possible GJIC-independent tumor suppression by connexins
we performed DNA array analysis to screen several well characterized
genes related to either tumor growth or metastasis. FGFR3 mRNA was
found to be down-regulated by 2.6-fold in Cx43-overexpressing
MDA-MB-231 cells in comparison to the control (Fig.
6, A and B,
boxed). Similarly, Cx26-overexpressing MDA-MB-231
cells down-regulated FGFR3 by 2.3-fold in comparison to the control
(data not shown). In accordance with DNA array data, Western blots
revealed that FGFR3 protein expression was reduced significantly by
30-50% in MDA-MB-231 cells engineered to overexpress Cx43 or Cx26 in
comparison to both wild-type and viral control cells (Fig. 6,
C and D). The DNA array analysis also revealed
that the chemokine receptor, CXCR4, was down-regulated in
Cx43-expressing MDA-MB-231 cells (Fig. 6, A and
B; compare spots in positions 3 and
4 from the left in the bottom row of each array);
however, the lack of a suitable antibody prevented this finding from
being confirmed at the protein level by Western blots.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 6.
FGFR3 was down-regulated in MDA-MB-231 cells
engineered to overexpress Cx43 or Cx26. FGFR3 mRNA was less
abundant in Cx43-overexpressing MDA-MB-231 cells in comparison to
wild-type tumor cells (A and B, square
outline). In accordance with the DNA array analysis, Western blot
analysis revealed that Cx43 was down-regulated in cells overexpressing
Cx43 or Cx26 in comparison with wild-type or viral controls
(C). HeLa cells were used as an internal control for
anti-FGFR3 antibody labeling. Quantification of three independent
experiments revealed a 30 and 50% reduction in FGFR3 expression in
comparison to the viral control when MDA-MB-231 cells overexpressed
Cx43 and Cx26, respectively (p < 0.05). No statistical
difference was found between wild-type and viral controls
(D).
|
|
 |
DISCUSSION |
Although normal human breast epithelial stem cells have been
reported to lack GJIC (27), differentiation of adult mammary epithelium
results in localized expression of Cx26 and Cx43 (4-8). Interestingly,
epithelial cells derived from normal human breast may exhibit GJIC and
a susceptibility to growth control or a GJIC deficiency and may be more
sensitive to growth stimulation (28), suggesting a correlation between
growth control and GJIC. It has been reported that there is a
down-regulation of connexins, gap junctions, and/or impaired GJIC in
human breast carcinomas and in other neoplastic cells (12, 29-31), but
the mechanism responsible for this down-regulation remains largely
unknown. We observed in this study not only that breast tumor cells can
have reduced connexin expression but also that they may have impaired
ability to transport, localize, and assemble connexins into gap
junctions. We have characterized diverse gap junction phenotypes
represented by three distinct human breast tumor cell lines. HBL100
cells displayed an acute deficiency in connexin expression, resulting in an absence of functional gap junction channels. In contrast to
HBL100 cells, a moderate level of Cx43 protein was detected in Hs578T
cells, and these cells exhibited a significant level of GJIC.
MDA-MB-231 cells represent a third phenotype in which GJIC was lacking,
even though the cells expressed significant amounts of Cx43. Although
no Cx26 protein was detected within these cells, it has been reported
that MDA-MB-231 have low levels of Cx26 mRNA, which can be
up-regulated if the cells are treated with the tumor promoter and
phorbol 12-myristate 13-acetate, a protein kinase C activator (17, 32).
MDA-MB-231 cells are malignant and may mimic breast carcinomas much
like what has been described in situ by Jamieson et
al. (19), where the cells continue to produce connexins but appear
to be defective in the ability to assemble gap junctions.
Together our results suggest that GJIC defects in human breast tumor
cells can occur at two distinct locations. First, as a consequence of
cell transformation the connexin gene may be turned off as evident by
the lack of Cx43 and Cx26 in HBL100 cells. Successful and efficient
rescue of GJIC in HBL100 cells upon infection with retroviruses that
encode connexins would suggest that they do not have further downstream
defects in the secretory pathway or in connexin assembly. These breast
tumor cells are not aggressive and will not grow in nude mice. Our
previous survey of human breast tumors in situ (7) suggests
that several human breast tumors lacking connexins may be suitable
candidates for GJIC rescue. It is likely that many breast tumors and
carcinomas of other types may exhibit a shutdown of the connexin
promoter (12, 33). In these cases and in breast tumor cells of similar
phenotype, exogenous expression of connexin or chemical up-regulation
of connexins may represent a useful approach to restore GJIC with a
possible therapeutic advantage of inhibiting tumor cell growth and
metastatic potential.
The second type of defect in GJIC represented by human MDA-MB-231
breast tumor cells occurs when cells continue to express connexins but
lack the appropriate protein folding, transport, or targeting machinery
to assemble functional gap junctions efficiently. Our studies revealed
that the overexpression of connexins alone in MDA-MB-231 cells did not
efficiently rescue GJIC. Therefore, the rescue of GJIC in human breast
tumor cells relies not only on the expression of connexins but also on
more downstream machinery to properly fold, assemble, or stabilize
connexins in functional gap junction channels.
Because MDA-MB-231 cells have defects in assembling both endogenous and
exogenous connexins, it was not a surprise to see that
connexin-expressing MDA-MB-231 cells did not exhibit significant differences in vitro growth. However, overexpression of Cx43
or Cx26 dramatically inhibited tumor formation in nude mice, resulting in a 6-fold decrease in tumor growth. Interestingly, Bond et
al. (10) found that Cx32-overexpressing C6 glioma cells did not have a reduced growth rate in vitro but that growth was
retarded in vivo; however, in their study GJIC was
known to be highly up-regulated. Our finding here is the first report
in which Cx43 and Cx26 not only exhibit differential growth effects
in vitro and in vivo but also, more intriguingly,
this was mediated via a GJIC-independent mechanism or via minimal
increases in GJIC. The fact that excised xenograph sections revealed
only intracellular Cx43 and no detectable gap junctions ruled out the
possibility that connexin-expressing MDA-MB-231 cells assembled
functional gap junctions more efficiently when implanted into the
milieu of the mammary fat pad. We cannot completely rule out the
possibility that a second connexin was up-regulated in the xenoplant
tumors, but this appears unlikely given the fact that it also should
have occurred in mice transplanted with MDA-MB-231 cells infected with
the empty retroviral vector.
It is becoming increasingly more evident that connexins may exert tumor
growth inhibition via both GJIC-dependent and -independent mechanisms. When Cx43 was expressed in human glioblastomas, cell proliferation was reduced dramatically in vitro and in
vivo in the absence of the establishment of GJIC (34). Moreover,
Omori and Yamasaki (35) showed that the expression of a mutant form of
Cx43 reverses the growth control properties of wild-type Cx43 in rat C6
glioma cells without affecting GJIC, suggesting a mechanism in which
Cx43-mediated growth suppression is unrelated to GJIC. In the case of
Neuro2a cells, expression of the carboxyl-terminal end of Cx43 alone
suppressed cell growth, suggesting a possible second mechanism by which
connexins may suppress tumor cell growth (36). Together with our
findings, this suggests that connexins may activate signaling pathways
that affect in vivo cell growth.
The question remains as to how connexin expression in the absence of
substantial increases in GJIC induces a reduction in tumor cell growth.
Given that our studies revealed little increase in GJIC upon high
expression of Cx43 or Cx26 in MDA-MB-231 cells we propose one of three
possible mechanisms. Because connexins are known to oligomerize into
hemichannels early within the secretory pathway (37, 38),
organelle-localized or plasma membrane-distributed hemichannels
possibly may be gated open to allow the passage of small molecules
(i.e. calcium) that signal to the nucleus. It is well
understood that connexin channels can allow the passage of secondary
messengers (39-41), and calcium has been demonstrated to regulate gene
transcription (42, 43). However, it remains to be demonstrated that
intracellular hemichannels can be gated open. In a second model, it is
conceivable that connexins, or more likely connexin fragments, regulate
gene transcription via possible interactions with transcription
factors. The fact that the carboxyl terminus of Cx43 can regulate tumor
cell growth in Neuro2a cells is consistent with this model (36).
Targeting of Cx43 to the nucleus is plausible given the putative
nuclear-targeting sequence encoded within the carboxyl terminus,
although there is no such putative nuclear-targeting sequence encoded
in Cx26. Finally, this study does not exclude the possibility that
minimal increases in GJIC have a dramatic effect on the inhibition of tumor cell growth in vivo. In our study, GJIC was assessed
via dye coupling methodologies that may be insensitive to minor changes in the intercellular coupling status of the tumor cells. Future expression of loss-of-function Cx26 mutants in GJIC-incompetent human
breast tumor cells should resolve this issue.
To further study the molecular mechanism of tumor suppression by
connexin expression we applied DNA array technology to screen a series
of genes closely related to tumor growth and metastasis. Western blot
analysis confirmed that FGFR3 was down-regulated in both Cx43- and
Cx26-expressing communication-deficient MDA-MB-231 cells, suggesting
that connexins do indeed have dual functions not only in mediating
cell-cell communication but also in regulating gene expression. Because
our DNA array study revealed a second candidate molecule (CXCR4)
down-regulated in cells expressing Cx43 or Cx26, it is quite possible
that larger arrays will reveal a number of cell growth- or
metastasis-related molecules that are regulated by connexin expression.
Although our array study included only a few selected genes, it
supports the conclusion that connexin expression can impact several
factors that play key roles in regulating tumor proliferation. For
instance, FGF/FGFR is a potent angiogenic factor that has been reported
to promote tumor growth as well as tumor invasion, a phenotype that is
blocked when this angiogenic marker is inhibited (44). The fact that connexins reduce the expression of FGFR3 raises the possibility of an
important role of connexins in inhibiting paracrine regulatory loops
involved in angiogenesis. Certainly additional studies are required to
address this important mechanism in appropriate in vivo
systems. The complementation of growth factors and the complexity of
receptor/growth factor binding within the milieu of the mammary fat pad
of nude mice in comparison to the simplicity of tumor cells grown in
culture may explain why connexin expression inhibited tumor growth
in vivo and not in vitro. These results strongly suggest that both Cx43 and Cx26 are potent tumor suppressors in vivo and emphasize the importance of examining the
tumor-suppressing properties of connexins in the three-dimensional
milieu of an organism. Finally, these studies highlight the possibility
that it may not be a prerequisite for connexins to be assembled into functional gap junctions in order to be of potential therapeutic value
in the treatment of human breast cancer. If connexins can be introduced
or chemically up-regulated in breast tumors they may act as a tumor
suppressor irrespective of their ability to assemble into functional
gap junctions efficiently.
In summary, we have shown that human breast tumor cells in
vitro have impaired or abolished GJIC. Moreover, we have
identified that the defect in GJIC may occur at the level of the gene
or during connexin folding, transport, and gap junction assembly. Retroviral-based delivery of connexin genes into human MDA-MB-231 breast tumor cells suppressed tumor growth in vivo, possibly
caused by the down-regulation of tumor growth-facilitating factors.
These results suggest that the retroviral delivery system in
combination with connexin gene therapy may have future value as part of
a treatment regimen for human breast cancer.
 |
ACKNOWLEDGEMENTS |
We thank C. H. Li, J. Bechberger, T. Jimenez, J. Mao, and Dr. C. C. G. Naus for contributing to
this study.
 |
FOOTNOTES |
*
This work was supported by grants from the McGill Centre for
Translational Research in Cancer and the Canadian Breast Cancer Research Initiative (to D. W. L. and M. A. J.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of Anatomy
and Cell Biology, University of Western Ontario, London, Ontario N6A 5C1, Canada. Tel.: 519-661-2111 (ext. 86827); Fax: 519-661-3936; E-mail: dwlaird@julian.uwo.ca.
Published, JBC Papers in Press, May 31, 2002, DOI 10.1074/jbc.M200797200
 |
ABBREVIATIONS |
The abbreviations used are:
GJIC, gap junctional
intercellular communication;
IP3, inositol-1,4,5-trisphosphate;
NRK, normal rat kidney;
Cx, connexin;
HMEC, human mammalian epithelial cells;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
FGFR, fibroblast growth
factor receptor.
 |
REFERENCES |
| 1.
|
Bruzzone, R.,
White, T. W.,
and Paul, D. L.
(1996)
Eur. J. Biochem.
238,
1-27[Medline]
[Order article via Infotrieve]
|
| 2.
|
Goodenough, D. A.,
Goliger, J. A.,
and Paul, D. L.
(1996)
Annu. Rev. Biochem.
65,
475-502[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Laird, D. W.
(1996)
J. Bioenerg. Biomembr.
28,
311-318[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Monaghan, P.,
Perusinghe, N.,
Carlile, G.,
and Evans, W. H.
(1994)
J. Histochem. Cytochem.
42,
931-938[Abstract]
|
| 5.
|
Monaghan, P.,
Clarke, C.,
Perusinghe, N. P.,
Moss, D. W.,
Chen, X. Y.,
and Evans, W. H.
(1996)
Exp. Cell Res.
223,
29-38[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Monaghan, P.,
and Moss, D.
(1996)
Cell Biol. Int.
20,
121-125[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Laird, D. W.,
Fistouris, P.,
Batist, G.,
Alpert, L.,
Huynh, H. T.,
Carystinos, G. D.,
and Alaoui-Jamali, M. A.
(1999)
Cancer Res.
59,
4104-4110[Abstract/Free Full Text]
|
| 8.
|
Pozzi, A.,
Risek, B.,
Kiang, D. T.,
Gilula, N. B.,
and Kumar, N. M.
(1995)
Exp. Cell Res.
220,
212-219[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Naus, C. C.,
Bechberger, J. F.,
Caveney, S.,
and Wilson, J. X.
(1991)
Neurosci. Lett.
126,
33-36[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Bond, S. L.,
Bechberger, J. F.,
Khoo, N. K.,
and Naus, C. C.
(1994)
Cell Growth & Differ.
5,
179-186[Abstract]
|
| 11.
|
Zhu, D.,
Caveney, S.,
Kidder, G. M.,
and Naus, C. C.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
1883-1887[Abstract/Free Full Text]
|
| 12.
|
Yamasaki, H.,
Omori, Y.,
Krutovskikh, V.,
Zhu, W.,
Mironov, N.,
Yamakage, K.,
and Mesnil, M.
(1999)
Novartis Foundation Symposium
219,
241-254[Medline]
[Order article via Infotrieve]
|
| 13.
|
Mehta, P. P.,
Perez-Stable, C.,
Nadji, M.,
Mian, M.,
Asotra, K.,
and Roos, B. A.
(1999)
Dev. Genet.
24,
91-110[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Saunders, M. M.,
Seraj, M. J., Li, Z.,
Zhou, Z.,
Winter, C. R.,
Welch, D. R.,
and Donahue, H. J.
(2001)
Cancer Res.
61,
1765-1767[Abstract/Free Full Text]
|
| 15.
|
Temme, A.,
Buchmann, A.,
Gabriel, H. D.,
Nelles, E.,
Schwarz, M.,
and Willecke, K.
(1997)
Curr. Biol.
7,
713-716[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Wilgenbus, K. K.,
Kirkpatrick, C. J.,
Knuechel, R.,
Willecke, K.,
and Traub, O.
(1992)
Intl. J. Cancer
51,
522-529[Medline]
[Order article via Infotrieve]
|
| 17.
|
Lee, S. W.,
Tomasetto, C.,
Paul, D.,
Keyomarsi, K.,
and Sager, R.
(1992)
J. Cell Biol.
118,
1213-1221[Abstract/Free Full Text]
|
| 18.
|
Lee, S. W.,
Tomasetto, C.,
and Sager, R.
(1991)
Proc. of the Natl. Acad. Sci., U. S. A.
88,
2825-2829
|
| 19.
|
Jamieson, S.,
Going, J. J.,
Darcy, R.,
and George, W. D.
(1998)
J. Pathol.
184,
37-43[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Laird, D. W.,
Castillo, M.,
and Kasprzak, L.
(1995)
J. Cell Biol.
131,
1193-1203[Abstract/Free Full Text]
|
| 21.
|
Laird, D. W.,
and Revel, J. P.
(1990)
J. Cell Sci.
97,
109-117[Abstract/Free Full Text]
|
| 22.
|
Galipeau, J. Li, H.,
Paquin, A.,
Sicilia, F.,
Karpati, G.,
and Nalbantoglu, J.
(1999)
Cancer Res.
59,
2384-2394[Abstract/Free Full Text]
|
| 23.
|
Mao, A. J.,
Bechberger, J.,
Lidington, D.,
Galipeau, J.,
Laird, D. W.,
and Naus, C. C.
(2000)
J. Biol. Chem.
275,
34407-34414[Abstract/Free Full Text]
|
| 24.
|
Jordan, K.,
Solan, J. L.,
Dominguez, M.,
Sia, M.,
Hand, A.,
Lampe, P. D.,
and Laird, D. W.
(1999)
Mol. Biol. Cell
10,
2033-2050[Abstract/Free Full Text]
|
| 25.
|
Woodward, T. L.,
Sia, M. A.,
Blaschuk, O. W.,
Turner, J. D.,
and Laird, D. W.
(1998)
J. Cell Sci.
111,
3529-3539[Abstract]
|
| 26.
|
Qin, H.,
Shao, Q.,
Belliveau, D. J.,
and Laird, D. W.
(2001)
Cell Comm. & Adhesion
8,
433-439
|
| 27.
|
Trosko, J. E.,
Chang, C. C.,
Wilson, M. R.,
Upham, B.,
Hayashi, T.,
and Wade, M.
(2000)
Methods
20,
245-264[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Kao, C. Y.,
Nomata, K.,
Oakley, C. S.,
Welsch, C. W.,
and Chang, C. C.
(1995)
Carcinogenesis
16,
531-538[Abstract/Free Full Text]
|
| 29.
|
Yamasaki, H.,
Mesnil, M.,
Omori, Y.,
Mironov, N.,
and Krutovskikh, V.
(1995)
Mutat. Res.
333,
181-188[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Yamasaki, H.
(1991)
Environ. Health Perspect.
93,
191-197[Medline]
[Order article via Infotrieve]
|
| 31.
|
Yamasaki, H.,
Omori, Y.,
Zaidan-Dagli, M. L.,
Mironov, N.,
Mesnil, M.,
and Krutovskikh, V.
(1999)
Cancer Detect. Prev.
23,
273-279[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Li, G. Y.,
Lin, H. H., Tu, Z. J.,
and Kiang, D. T.
(1998)
Gene
209,
139-147[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Sawey, M. J.,
Goldschmidt, M. H.,
Risek, B.,
Gilula, N. B.,
and Lo, C. W.
(1996)
Mol. Carcinog.
17,
49-61[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Huang, R. P.,
Fan, Y.,
Hossain, M. Z.,
Peng, A.,
Zeng, Z. L.,
and Boynton, A. L.
(1998)
Cancer Res.
58,
5089-5096[Abstract/Free Full Text]
|
| 35.
|
Omori, Y.,
and Yamasaki, H.
(1998)
Int. J. Cancer
78,
446-453[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Moorby, C.,
and Patel, M.
(2001)
Exp. Cell Res.
271,
238-248[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Musil, L. S.,
and Goodenough, D. A.
(1993)
Cell
74,
1065-1077[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Falk, M. M.,
Kumar, N. M.,
and Gilula, N. B.
(1994)
J. Cell Biol.
127,
343-355[Abstract/Free Full Text]
|
| 39.
|
Sneyd, J.,
Wilkins, M.,
Strahonja, A.,
and Sanderson, M. J.
(1998)
Biophys. Chem.
72,
101-109[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Thomas, A. P.,
Bird, G. S.,
Hajnoczky, G.,
Robb-Gaspers, L. D.,
and Putney, J. W., Jr.
(1996)
FASEB J.
10,
1505-1517[Abstract]
|
| 41.
|
Goldberg, G. S.,
Lampe, P. D.,
Sheedy, D.,
Stewart, C. C.,
Nicholson, B. J.,
and Naus, C. C.
(1998)
Exp. Cell Res.
239,
82-92[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Crabtree, G. R.
(1999)
Cell
96,
611-614[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
West, A. E.,
Chen, W. G.,
Dalva, M. B.,
Dolmetsch, R. E.,
Kornhauser, J. M.,
Shaywitz, A. J.,
Takasu, M. A.,
Tao, X.,
and Greenberg, M. E.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
11024-11031[Abstract/Free Full Text]
|
| 44.
|
Cross, M. J.,
and Claesson-Welsh, L.
(2001)
Trends Pharmacol. Sci.
22,
201-207[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. OZAWA, H. MUTAI, T. MATSUNAGA, Y. TOKUMARU, M. FUJII, K. SAKAMOTO, T. TOMITA, and K. OGAWA
Promoted Cell Proliferation by Connexin 30 Gene Transfection to Head-and-Neck Cancer Cell Line
Anticancer Res,
June 1, 2009;
29(6):
1981 - 1985.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Schalper, N. Palacios-Prado, M. A. Retamal, K. F. Shoji, A. D. Martinez, and J. C. Saez
Connexin Hemichannel Composition Determines the FGF-1-induced Membrane Permeability and Free [Ca2+]i Responses
Mol. Biol. Cell,
August 1, 2008;
19(8):
3501 - 3513.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Langlois, K. N. Cowan, Q. Shao, B. J. Cowan, and D. W. Laird
Caveolin-1 and -2 Interact with Connexin43 and Regulate Gap Junctional Intercellular Communication in Keratinocytes
Mol. Biol. Cell,
March 1, 2008;
19(3):
912 - 928.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. L. Hutnik, C. E. Pocrnich, H. Liu, D. W. Laird, and Q. Shao
The Protective Effect of Functional Connexin43 Channels on a Human Epithelial Cell Line Exposed to Oxidative Stress
Invest. Ophthalmol. Vis. Sci.,
February 1, 2008;
49(2):
800 - 806.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ezumi, H. Yamamoto, K. Murata, M. Higashiyama, B. Damdinsuren, Y. Nakamura, N. Kyo, J. Okami, C. Y. Ngan, I. Takemasa, et al.
Aberrant Expression of Connexin 26 Is Associated with Lung Metastasis of Colorectal Cancer
Clin. Cancer Res.,
February 1, 2008;
14(3):
677 - 684.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Tong, T. Y. Li, K. E. Naus, D. Bai, and G. M. Kidder
In vivo analysis of undocked connexin43 gap junction hemichannels in ovarian granulosa cells
J. Cell Sci.,
November 15, 2007;
120(22):
4016 - 4024.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Langlois, A. C. Maher, J. L. Manias, Q. Shao, G. M. Kidder, and D. W. Laird
Connexin Levels Regulate Keratinocyte Differentiation in the Epidermis
J. Biol. Chem.,
October 12, 2007;
282(41):
30171 - 30180.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Shen, P. R. Khusial, X. Li, H. Ichikawa, A. P. Moreno, and G. S. Goldberg
Src Utilizes Cas to Block Gap Junctional Communication Mediated by Connexin43
J. Biol. Chem.,
June 29, 2007;
282(26):
18914 - 18921.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Wang, V. M. Berthoud, and E. C. Beyer
Connexin43 increases the sensitivity of prostate cancer cells to TNF{alpha}-induced apoptosis
J. Cell Sci.,
January 15, 2007;
120(2):
320 - 329.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M.J. Conklin, J. F. Bechberger, D. MacFabe, N. Guthrie, E. M. Kurowska, and C. C. Naus
Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells
Carcinogenesis,
January 1, 2007;
28(1):
93 - 100.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kalra, Q. Shao, H. Qin, T. Thomas, M. A. Alaoui-Jamali, and D. W. Laird
Cx26 inhibits breast MDA-MB-435 cell tumorigenic properties by a gap junctional intercellular communication-independent mechanism
Carcinogenesis,
December 1, 2006;
27(12):
2528 - 2537.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Squecco, C. Sassoli, F. Nuti, M. Martinesi, F. Chellini, D. Nosi, S. Zecchi-Orlandini, F. Francini, L. Formigli, and E. Meacci
Sphingosine 1-Phosphate Induces Myoblast Differentiation through Cx43 Protein Expression: A Role for a Gap Junction-dependent and -independent Function
Mol. Biol. Cell,
November 1, 2006;
17(11):
4896 - 4910.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X.-Q. Gong, Q. Shao, C. S. Lounsbury, D. Bai, and D. W. Laird
Functional Characterization of a GJA1 Frameshift Mutation Causing Oculodentodigital Dysplasia and Palmoplantar Keratoderma
J. Biol. Chem.,
October 20, 2006;
281(42):
31801 - 31811.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. McLachlan, Q. Shao, H.-l. Wang, S. Langlois, and D. W. Laird
Connexins Act as Tumor Suppressors in Three-dimensional Mammary Cell Organoids by Regulating Differentiation and Angiogenesis.
Cancer Res.,
October 15, 2006;
66(20):
9886 - 9894.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. B. Francis and C. W. Lo
Primordial germ cell deficiency in the connexin 43 knockout mouse arises from apoptosis associated with abnormal p53 activation
Development,
September 1, 2006;
133(17):
3451 - 3460.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. E. Chadjichristos, C. M. Matter, I. Roth, E. Sutter, G. Pelli, T. F. Luscher, M. Chanson, and B. R. Kwak
Reduced Connexin43 Expression Limits Neointima Formation After Balloon Distension Injury in Hypercholesterolemic Mice
Circulation,
June 20, 2006;
113(24):
2835 - 2843.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Thomas, K. Jordan, J. Simek, Q. Shao, C. Jedeszko, P. Walton, and D. W. Laird
Mechanisms of Cx43 and Cx26 transport to the plasma membrane and gap junction regeneration
J. Cell Sci.,
October 1, 2005;
118(19):
4451 - 4462.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Lahlou, M. Fanjul, L. Pradayrol, C. Susini, and S. Pyronnet
Restoration of Functional Gap Junctions through Internal Ribosome Entry Site-Dependent Synthesis of Endogenous Connexins in Density-Inhibited Cancer Cells
Mol. Cell. Biol.,
May 15, 2005;
25(10):
4034 - 4045.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Shao, H. Wang, E. McLachlan, G. I.L. Veitch, and D. W. Laird
Down-regulation of Cx43 by Retroviral Delivery of Small Interfering RNA Promotes an Aggressive Breast Cancer Cell Phenotype
Cancer Res.,
April 1, 2005;
65(7):
2705 - 2711.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Leithe and E. Rivedal
Ubiquitination and Down-regulation of Gap Junction Protein Connexin-43 in Response to 12-O-Tetradecanoylphorbol 13-Acetate Treatment
J. Biol. Chem.,
November 26, 2004;
279(48):
50089 - 50096.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. T. Fu, J. F. Bechberger, M. A. Ozog, B. Perbal, and C. C. Naus
CCN3 (NOV) Interacts with Connexin43 in C6 Glioma Cells: POSSIBLE MECHANISM OF CONNEXIN-MEDIATED GROWTH SUPPRESSION
J. Biol. Chem.,
August 27, 2004;
279(35):
36943 - 36950.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. I. Veitch, J. E. I. Gittens, Q. Shao, D. W. Laird, and G. M. Kidder
Selective assembly of connexin37 into heterocellular gap junctions at the oocyte/granulosa cell interface
J. Cell Sci.,
June 1, 2004;
117(13):
2699 - 2707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Thomas, D. Telford, and D. W. Laird
Functional Domain Mapping and Selective Trans-dominant Effects Exhibited by Cx26 Disease-causing Mutations
J. Biol. Chem.,
April 30, 2004;
279(18):
19157 - 19168.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Leithe and E. Rivedal
Epidermal growth factor regulates ubiquitination, internalization and proteasome-dependent degradation of connexin43
J. Cell Sci.,
March 1, 2004;
117(7):
1211 - 1220.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. B. Alexander, H. Ichikawa, J. F. Bechberger, V. Valiunas, M. Ohki, C. C. G. Naus, T. Kunimoto, H. Tsuda, W. T. Miller, and G. S. Goldberg
Normal Cells Control the Growth of Neighboring Transformed Cells Independent of Gap Junctional Communication and Src Activity
Cancer Res.,
February 15, 2004;
64(4):
1347 - 1358.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Huard, N. Druesne, D. Guyonnet, M. Thomas, A. Pagniez, A.-M. Le Bon, P. Martel, and C. Chaumontet
Diallyl disulfide (DADS) enhances gap-junctional intercellular communication by both direct and indirect mechanisms in rat liver cells
Carcinogenesis,
January 1, 2004;
25(1):
91 - 98.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Iacobas, M. Urban-Maldonado, S. Iacobas, E. Scemes, and D. C. Spray
Array analysis of gene expression in connexin-43 null astrocytes
Physiol Genomics,
November 11, 2003;
15(3):
177 - 190.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-W. Zhang, M. Kaneda, and I. Morita
The Gap Junction-independent Tumor-suppressing Effect of Connexin 43
J. Biol. Chem.,
November 7, 2003;
278(45):
44852 - 44856.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Qin, Q. Shao, S. A. Igdoura, M. A. Alaoui-Jamali, and D. W. Laird
Lysosomal and Proteasomal Degradation Play Distinct Roles in the Life Cycle of Cx43 in Gap Junctional Intercellular Communication-deficient and -competent Breast Tumor Cells
J. Biol. Chem.,
August 8, 2003;
278(32):
30005 - 30014.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Olbina and W. Eckhart
Mutations in the Second Extracellular Region of Connexin 43 Prevent Localization to the Plasma Membrane, but Do Not Affect Its Ability to Suppress Cell Growth
Mol. Cancer Res.,
July 1, 2003;
1(9):
690 - 700.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H.-C. Lin, J. Yang, S. Liu, T. Takano, X. Wang, Q. Gao, K. Willecke, and M. Nedergaard
Connexin Mediates Gap Junction-Independent Resistance to Cellular Injury
J. Neurosci.,
January 15, 2003;
23(2):
430 - 441.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|